SECONDARY PREVENTION OF CORONARY-DISEASE WITH LIPID-LOWERING DRUGS

被引：0
作者：
不详
机构：
来源：
LANCET | 1989年 / 1卷 / 8636期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：473 / 474
页数：2
相关论文
共 50 条
[41]   Lipid-lowering drugs and homocysteine - A comparison between statins and other lipid-lowering drugs [J].
Jankowski, P ;
Kawecka-Jaszcz, K .
ATHEROSCLEROSIS, 2004, 172 (01) :191-194
[42]   LIPID CONTROL AND USE OF LIPID-LOWERING DRUGS FOR SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS IN TAIWAN: THE TAIWANESE SECONDARY PREVENTION FOR PATIENTS WITH ATHEROSCLEROTIC DISEASE (T-SPARCLE) REGISTRY [J].
Yin, Wei-Hsian ;
Yin, Wei-Hsian .
HEART, 2012, 98 :E10-E11
[43]   Secondary prevention of coronary heart disease with cholesterol-lowering drugs [J].
Pedersen, TR .
INTERNIST, 1995, 36 (12) :1174-1178
[44]   Factors associated with non-use of lipid-lowering drugs in secondary prevention of coronary heart diseases. EUROASPIRE study [J].
Pyorala, K ;
Vanuzzo, D ;
Ambrosio, GB ;
DeBacquer, D ;
DeBacker, G .
ATHEROSCLEROSIS, 1997, 134 (1-2) :132-132
[45]   Pharmacoeconomics of lipid-lowering drugs [J].
Dean G. Smith .
Current Atherosclerosis Reports, 2003, 5 (1) :67-72
[46]   Long-term effects on cholesterol levels and the utilization of lipid-lowering drugs of a hospital-based programme for secondary prevention of coronary artery disease [J].
Stagmo, M ;
Westin, L ;
Carlsson, R ;
Israelsson, B .
JOURNAL OF CARDIOVASCULAR RISK, 2001, 8 (04) :243-248
[47]   Secondary preventive potential of lipid-lowering drugs - The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) [J].
deFaire, U ;
Ericsson, CG ;
Grip, L ;
Nilsson, J ;
Svane, B ;
Hamsten, A .
EUROPEAN HEART JOURNAL, 1996, 17 :37-42
[48]   Choice of lipid-lowering drugs [J].
不详 .
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 1998, 40 (1042) :117-122
[49]   Pharmacogenetics of lipid-lowering drugs [J].
Kivisto, K. T. .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 :47-47
[50]   Lipid-lowering drugs and cataract [J].
Bezin, J. ;
Mansiaux, Y. ;
Pariente, A. .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 :6-6
12345